IBDEI1EH ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25109,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,25109,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,25110,0)
 ;;=203.01^^145^1535^105
 ;;^UTILITY(U,$J,358.3,25110,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25110,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,25110,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,25110,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,25111,0)
 ;;=238.6^^145^1535^108
 ;;^UTILITY(U,$J,358.3,25111,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25111,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,25111,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,25111,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,25112,0)
 ;;=205.00^^145^1535^4
 ;;^UTILITY(U,$J,358.3,25112,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25112,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,25112,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,25112,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,25113,0)
 ;;=205.01^^145^1535^6
 ;;^UTILITY(U,$J,358.3,25113,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25113,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,25113,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,25113,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,25114,0)
 ;;=205.10^^145^1535^19
 ;;^UTILITY(U,$J,358.3,25114,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25114,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,25114,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,25114,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,25115,0)
 ;;=205.11^^145^1535^21
 ;;^UTILITY(U,$J,358.3,25115,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25115,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,25115,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,25115,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,25116,0)
 ;;=289.0^^145^1535^55
 ;;^UTILITY(U,$J,358.3,25116,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25116,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,25116,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,25116,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,25117,0)
 ;;=238.4^^145^1535^109
 ;;^UTILITY(U,$J,358.3,25117,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25117,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,25117,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,25117,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,25118,0)
 ;;=V58.61^^145^1535^126
 ;;^UTILITY(U,$J,358.3,25118,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25118,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,25118,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,25118,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,25119,0)
 ;;=282.49^^145^1535^117
 ;;^UTILITY(U,$J,358.3,25119,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25119,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,25119,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,25119,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,25120,0)
 ;;=289.89^^145^1535^15
 ;;^UTILITY(U,$J,358.3,25120,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25120,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,25120,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,25120,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,25121,0)
 ;;=238.79^^145^1535^88
 ;;^UTILITY(U,$J,358.3,25121,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25121,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,25121,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,25121,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,25122,0)
 ;;=287.30^^145^1535^110
 ;;^UTILITY(U,$J,358.3,25122,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25122,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,25122,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,25122,2)
 ;;=^332841
